论文部分内容阅读
目的分析子宫内膜癌患者血清蛋白质谱,以筛选其特异肿瘤标志物。方法对青岛医学院附属医院200402-20051052例子宫内膜癌患者及44例对照组采用表面加强的激光解析/电离化时间-飞行质谱(SELDITOFMS)技术结合弱阴离子交换芯片(WCX2)检测其血清蛋白质谱,用BiomarkWizard软件分析差异蛋白峰,评价该技术的应用价值,并搜索鉴定蛋白。结果在分子质量0～50000u范围内,子宫内膜癌组与其对照组发现6个有统计学意义(P<0.05)的差异蛋白质:2748、4106、4708、8895、9412、18344u,检测二者的敏感度为77.1%～87.5%,特异度为75.0%～90.0%。子宫内膜癌Ⅰ期组与Ⅱ、Ⅲ、Ⅳ期组发现4个有统计学意义的差异蛋白质:2748、4356、6442、11733u,区分二组的敏感度为75.9%～82.7%,特异度为73.9%～87.0%。子宫内膜癌高分化组与中、低分化组发现4个有统计学意义的差异蛋白质:5647、6888、7979、8059u,区分二组的敏感度为77.3%～86.4%,特异度为76.7%～86.7%。2748u的差异蛋白与Histatin-31/24(Histatin-5)相符。结论SELDITOFMS技术无创有效,有望辅助子宫内膜癌筛查及早期诊断。
Objective To analyze the serum protein profiles of patients with endometrial cancer to screen for their specific tumor markers. Methods 200402-20051052 cases of endometrial cancer patients in Qingdao Medical College Hospital and 44 cases of control group were analyzed by surface enhanced laser desorption / ionization time-of-flight mass spectrometry (SELDITOFMS) combined with weak anion exchange chip (WCX2) Spectrum, using the BiomarkWizard software analysis of differential protein peaks, evaluate the value of the technology, and search for identification of proteins. Results There were 6 differentially expressed proteins in the endometrial carcinoma group and the control group with statistical significance (P <0.05) in the range of 0-50000u molecular weight: 2748,4106,4708,8895,9412,18344u, Sensitivity was 77.1% ~ 87.5%, specificity was 75.0% ~ 90.0%. Four endometrial cancer stage Ⅰ and Ⅱ, Ⅲ, Ⅳ group found four statistically significant differences in the protein: 2748,4356,6442,11733u, the sensitivity of the distinction between the two groups was 75.9% to 82.7%, the specificity was 73.9% ~ 87.0%. There were four statistically significant differential proteins in the well-differentiated and moderately differentiated endometrial cancer groups: 5647,6888,7979,8059u, the sensitivity, specificity and specificity were 77.3% -86.4%, 76.7% ~ 86.7%. The 2748u differential protein is consistent with Histatin-31/24 (Histatin-5). Conclusion SELDITOFMS technique is noninvasive and effective, which is expected to assist screening and early diagnosis of endometrial cancer.